JB Pharma ( formerly known as JB Chemicals and Pharmaceuticals Ltd, JBCPL and Unique Pharmaceuticals) is an Indian pharmaceutical company with Headquarters at Mumbai, Maharashtra, India.

The company was originally promoted and incorporated in Maharashtra by J B Mody along with his two brothers, D.B. Mody and S.B. Mody as J B Mody Chemicals & Pharmaceuticals in the year 1976. The company was a part of Unique Group of companies.

Later, the name was changed to J.B. Chemical and Pharmaceuticals Ltd. and a fresh Certificate of Incorporation upon change of name was issued on 21st August, 1985 by the Registrar of Companies, Maharashtra at Mumbai.

The company has operational presence in more than 50 countries and has 11 state–of–the–art manufacturing units located at Belapur, Panoli, Ankleshwar and Daman.

It exports to over 40 countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries.

JBCPL owns three subsidiaries namely J B Life Science Overseas (India), OOO Unique Pharmaceuticals Laboratories (Moscow, Russia) and J B Healthcare (Jersey, Channel Islands).

It holds a domestic sales force of 1,000 people, while 17 internationally approved state of the art manufacturing units, a Research and Development Centre, and subsidiaries abroad.

The company also undertakes Contract Research and Manufacturing Services (CRAMS) for companies in US, Europe, Australia and South Africa.

The company specializes in manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams and ointments, lozenges, cough syrups, herbal liquids and capsules, diagnostics, generic drugs, Active Pharmaceutical Ingredients (APIs).

In 1985, the company got publicly listed and expanded from API to Formulations.

It is engaged in developing formulations in therapeutic segment such as diabetic, cardiovascular, urology, psychiatry, and so on. It forayed into the cardiac segment with the revolutionary product Nicardia in the year 1980.

It is one of the largest manufacturers of Diclofenac Sodium and Metronidazole. Brands namely Cilacar, Metrogyl, Rantac and Nicardia form a significant part of the company's sales. The company’s another product, Cilacar went on to become one of the leading brand in cardiology and nephrology, earning the company the nickname House of CCBs

The firm filed its first Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (USFDA) in 2003. It is also the first Indian Company to receive permission from Drugs Controllers General of India (DCGI) to market Rantac CD formulations.

In 2008, it made a strategic investment in a company in South Africa called Biotech Laboratories.

Leading private equity firm Kohlberg Kravis Roberts & Co. Inc. (KKR), acquired 54 percent stake of JBCPL for around Rs 3700 crore in 2020.

The company acquired Azmarda brand indicated for heart failure patients with reduced ejection fraction (HFrEF) from Novartis AG Switzerland for India in 2021. The company was then renamed as JB Pharma

Some of the major brands of the company JB Pharma include Cilacar, Rantac, Nicardia, Metrogyl, Cilacar-T, Rantac-Dom, Rantac Mps, Cilacar-M, Metrogyl IV, Bizfer-Xt, Of, Cilacar TC, Zecuf, Beta-Nicardia, Myotan, Panum L, Cadomer, Gutpro, Zott-P, Cilacar C, Rantac-Mps LA, Nimek-Para, Dispred, Panum-D, Myotan CT, Metrogyl-F, Ifimol, Lekace-Serra, Bisotab, Manogyl ,Panum, Ofcef, Metrogyl Comp. Plus, Moviz-3D, Laxan, Udicol, Fitgel, DDD, Uni-K2-7, Lekace-P, Rifa Metrogyl, Trazograf, Ornigyl, Vasolip, Nimek, Chymolek, Cilacar Nb, Rosugoal Trio, Laxolite and Nimek-Spas M